Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07664787

Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

Prospective, Multi-Center, Randomized, shame-Controlled, Uptake clinical trial to evaluate the efficacy and safety of the six-channel radio-frequency（RF) renal denervation system-comprising the six-channel RF generator (specification model: 25D1G, software release version: SRG-V1) and the disposable ultra-guiding RF denervation catheter (specification model: 25C6W127F115T)-for renal denervation in patients with grade I hypertension and without taking antihypertensive medicines.

Official title: Safety and Efficacy of Six-Channel Radiofrequency Ablation System for Renal Denervation in Patients With Untreated Grade I Hypertension: a Pilot Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-07-01

Completion Date

2027-12-30

Last Updated

2026-06-24

Healthy Volunteers

Conditions

Hypertension Grade 1

Interventions

DEVICE

Six-channel RF Renal Denervation System

DSA-guided percutaneous renal sympathetic denervation using a six-channel RF renal denervation system-comprising the six-channel radiofrequency generator (specification model: 25D1G, software release version: SRG-V1) and the ultra-guiding radiofrequency denervation catheter (specification model: 25C6W127F115T)

PROCEDURE

Parallel controln with sham operation(there is no rade and/or generic name,It is a blank control sham operation)

Sham procedure including femoral artery puncture and selective renal angiography; the six-channel radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

Inclusion Criteria: 1. Male or female, aged 18 to 65 years inclusive 2. Hypertension duration longer than 3 months 3. Hypertensive subjects who have been stopped taking antihypertensive drugs continuously and stably for at least 4 weeks or who do not take antihypertensive drugs , with office systolic/diastolic blood pressure still ≥140/90 mmHg and \<160/100 mmHg, and 24-hour ambulatory mean systolic /diastolic pressure ≥130/80 mmHg and \<140/90 mmHg; 4. The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form. Exclusion Criteria: 1. Pregnant or breastfeeding, or planning pregnancy during the study. 2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter \<3 mm, or treatable segment length \<20 mm). 3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis or eGFR\<40mL/min/1.73m2。 4. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.). 5. Allergic to contrast agents. 6. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months. 7. Orthostatic hypotension. 8. Type 1 diabetes mellitus. 9. History of bleeding diathesis and haematological disorders or coagulopathy 10. History of thromboembolic event within 6 months. 11. History of stroke or transient ischemic attack (TIA) within 6 months. 12. Severe peripheral arterial disease or unstable abdominal aortic aneurysm. 13. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period. NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months. 14. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker. 15. Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS. 16. Acute or severe systemic infection. 17. Other conditions deemed unsuitable for participation by the investigator.